IA
IBRX icon

IFP Advisors’s ImmunityBio IBRX Stock Holding History

IFP Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Sell
1,700
-15
-0.9% -$114 ﹤0.01% 3154
2026
Q1 		$13.2K Buy
1,715
+1,328
+343% +$9.09K ﹤0.01% 3022
2025
Q4 		$766 Sell
387
-27
-7% -$61 ﹤0.01% 4156
2025
Q3 		$1.02K Sell
414
-25
-6% -$64 ﹤0.01% 3961
2025
Q2 		$1.16K Buy
+439
New +$1.18K ﹤0.01% 4169
2025
Q1 		– Sell
-85
Closed -$218 – 4471
2024
Q4 		$218 Buy
+85
New +$354 ﹤0.01% 3694
2021
Q2 		– Sell
-200
Closed -$3.3K – 3137
2021
Q1 		$5K Buy
+200
New +$5.18K ﹤0.01% 2413

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IFP Advisors's IBRX Position: Q2 2026 in Review

IFP Advisors reduced its ImmunityBio (IBRX) stake by 0.87% in Q2 2026, selling an estimated $114 and leaving 1,700 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

IFP Advisors first reported a position in IBRX in Q1 2021 and has held it in 7 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • IFP Advisors held 1,700 shares of ImmunityBio worth $14.9K as of Q2 2026.
  • IFP Advisors sold 15 ImmunityBio shares in Q2 2026, an estimated $114.
  • ImmunityBio made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3154 holding.
  • IFP Advisors first reported a position in ImmunityBio in Q1 2021 and has held it in 7 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.